Compare

Amgen vs AbbVie

MonkScore ranges and fundamentals, side by side

Key facts

Amgen and AbbVie: key facts

  • In fiscal 2025, Amgen Inc. reported revenue of $36.7B and net income of $7.7B.
  • In fiscal 2025, AbbVie Inc. reported revenue of $61.2B and net income of $4.2B.
  • Amgen Inc.'s revenue grew 9.1% a year from fiscal 2021 to fiscal 2025.
  • AbbVie Inc.'s revenue grew 2.1% a year from fiscal 2021 to fiscal 2025.
  • Amgen Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • AbbVie Inc.'s free cash flow was positive in 5 of the 5 fiscal years from 2021 to 2025.
  • In the twelve months to 30 June 2026, Amgen Inc. reported revenue of $38.1B and net income of $8.7B.
  • In the twelve months to 30 June 2026, AbbVie Inc. reported revenue of $64.4B and net income of $6.3B.

Side by side

Amgen and AbbVie, side by side

Each figure is in the company's reporting currency, with its fiscal year or the date of its last report.

FigureAmgen Inc.NASDAQ:AMGNAbbVie Inc.NYSE:ABBV
MonkScore
MonkScore range90–100as of October 202690–100as of October 2026
Sector rank65 of 628 in Healthcare64 of 628 in Healthcare
How this score is madeDisclaimer
Profile
SectorHealthcareHealthcare
IndustryDrug Manufacturers - GeneralDrug Manufacturers - General
Latest fiscal year
Revenue$36.7BFY 2025$61.2BFY 2025
Net income$7.7BFY 2025$4.2BFY 2025
Free cash flow$8.1BFY 2025$17.8BFY 2025
Operating cash flow$10.0BFY 2025$19.0BFY 2025
Total debt$54.6BFY 2025$69.1BFY 2025
Cash$9.1BFY 2025$5.2BFY 2025
Last 12 months
Revenue$38.1Bto 30 June 2026$64.4Bto 30 June 2026
Net income$8.7Bto 30 June 2026$6.3Bto 30 June 2026
Free cash flow$10.2Bto 30 June 2026$18.2Bto 30 June 2026
Operating cash flow$12.5Bto 30 June 2026$19.5Bto 30 June 2026
Total debt$57.3Bto 30 June 2026$70.8Bto 30 June 2026
Cash$14.0Bto 30 June 2026$6.6Bto 30 June 2026

MonkStreet provides research, not investment advice.